-
公开(公告)号:US07244763B2
公开(公告)日:2007-07-17
申请号:US10774260
申请日:2004-02-06
申请人: Larry D. Bratton , Xue-Min Cheng , Noe Erasga , Gary F. Filzen , Andrew G. Geyer , Chitase Lee , Bharat K. Trivedi , Paul C. Unangst
发明人: Larry D. Bratton , Xue-Min Cheng , Noe Erasga , Gary F. Filzen , Andrew G. Geyer , Chitase Lee , Bharat K. Trivedi , Paul C. Unangst
IPC分类号: A61K31/235 , A61K31/38 , A61K31/35 , C07D405/00 , C07D261/06
CPC分类号: C07D213/74 , C07C59/72 , C07C62/34 , C07C323/20 , C07C323/21 , C07C323/22 , C07C323/25 , C07C323/62 , C07C2601/02 , C07C2602/08 , C07C2602/10 , C07C2603/18 , C07D213/34 , C07D215/36 , C07D261/08 , C07D263/57 , C07D263/58 , C07D307/79 , C07D311/58 , C07D333/22 , C07D333/60 , C07D405/12 , C07D413/12 , C07D417/12
摘要: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
摘要翻译: 本发明涉及改变PPAR活性的化合物。 本发明还涉及化合物的药学上可接受的盐,包含该化合物或其盐的药学上可接受的组合物,以及使用它们作为治疗或预防哺乳动物血脂异常,高胆固醇血症,肥胖症,高血糖症,动脉粥样硬化,高甘油三酯血症和高胰岛素血症的治疗剂的方法 。 本发明还涉及制备所公开的化合物的方法。
-
2.
公开(公告)号:US06939875B2
公开(公告)日:2005-09-06
申请号:US10979617
申请日:2004-11-02
申请人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号: A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07D213/02
CPC分类号: C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
摘要翻译: 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐,包含化合物或其盐的药学上可接受的组合物,以及使用它们作为治疗或预防血脂异常,高胆固醇血症,肥胖,进食障碍,高血糖症,动脉粥样硬化,高甘油三酯血症,高胰岛素血症和 哺乳动物中的糖尿病以及抑制食欲和调节哺乳动物瘦素水平的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号:US06964983B2
公开(公告)日:2005-11-15
申请号:US10979629
申请日:2004-11-02
申请人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号: A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07C51/00
CPC分类号: C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
-
4.
公开(公告)号:US06875780B2
公开(公告)日:2005-04-05
申请号:US10347749
申请日:2003-01-22
申请人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人: Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号: A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07D213/02 , A61K31/47
CPC分类号: C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
摘要翻译: 本发明涉及改变PPAR活性的化合物。 本发明还涉及化合物的药学上可接受的盐,包含该化合物或其盐的药学上可接受的组合物,以及使用它们作为治疗或预防哺乳动物血脂异常,高胆固醇血症,肥胖症,高血糖症,动脉粥样硬化,高甘油三酯血症和高胰岛素血症的治疗剂的方法 。 本发明还涉及制备所公开的化合物的方法。
-
公开(公告)号:US06867224B2
公开(公告)日:2005-03-15
申请号:US10324266
申请日:2002-12-19
IPC分类号: A61K31/426 , A61K31/427 , A61K31/4725 , A61P3/00 , A61P3/06 , A61P3/10 , A61P9/10 , C07D277/26 , C07D277/30 , C07D417/12
CPC分类号: C07D417/12 , C07D277/26
摘要: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
摘要翻译: 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐,包含化合物或其盐的药学上可接受的组合物,以及使用它们作为治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号:US07109222B2
公开(公告)日:2006-09-19
申请号:US11025271
申请日:2004-12-24
IPC分类号: A61K31/426 , C07D277/30
CPC分类号: C07D417/12 , C07D277/26
摘要: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
-
7.
公开(公告)号:USRE39916E1
公开(公告)日:2007-11-06
申请号:US11288022
申请日:2005-11-28
申请人: Bruce J. Auerbach , Larry D. Bratton , Gary Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人: Bruce J. Auerbach , Larry D. Bratton , Gary Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号: A61K31/44 , C07D213/02
CPC分类号: C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
摘要翻译: 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐,包含其盐的化合物的药学上可接受的组合物,以及使用它们作为治疗或预防血脂异常,高胆固醇血症,肥胖症,进食障碍,高血糖症,动脉粥样硬化,高甘油三酯血症,高胰岛素血症和 哺乳动物中的糖尿病以及抑制哺乳动物的食欲和调节瘦素水平的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号:US07067538B2
公开(公告)日:2006-06-27
申请号:US10442917
申请日:2003-05-21
申请人: Larry D. Bratton , Alexander J. Bridges , David T. Connor , Steven R. Miller , Yuntao Song , Kuai-Lin Sun , Bharat K. Trivedi , Paul C. Unangst
发明人: Larry D. Bratton , Alexander J. Bridges , David T. Connor , Steven R. Miller , Yuntao Song , Kuai-Lin Sun , Bharat K. Trivedi , Paul C. Unangst
CPC分类号: C07C311/03 , C07C311/27 , C07C317/18 , C07C317/24 , C07C317/28 , C07C317/44 , C07D213/50 , C07D233/64 , C07D239/26 , C07D261/08 , C07D263/32 , C07D277/10 , C07D277/26 , C07D307/46 , C07D307/71 , C07D307/80 , C07D333/22 , C07D333/38 , C07D333/44 , C07D413/04
摘要: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
摘要翻译: 本发明涉及可用于治疗趋化因子介导的病症的砜。 在某些实施方案中,本发明涉及作为MCP-1受体拮抗剂的化合物。
-
公开(公告)号:US5331006A
公开(公告)日:1994-07-19
申请号:US726656
申请日:1991-07-12
申请人: David C. Horwell , Julian Aranda , Corinne Augelli-Szafran , Hans-Jurgen Betche , Ann Holmes , Michael D. Mullican , Martyn C. Pritchard , Reginald S. Richardson , Edward Roberts , Bruce D. Roth , Bradley D. Tait , Bharat K. Trivedi , Uwe Trostmann , Paul C. Unangst
发明人: David C. Horwell , Julian Aranda , Corinne Augelli-Szafran , Hans-Jurgen Betche , Ann Holmes , Michael D. Mullican , Martyn C. Pritchard , Reginald S. Richardson , Edward Roberts , Bruce D. Roth , Bradley D. Tait , Bharat K. Trivedi , Uwe Trostmann , Paul C. Unangst
IPC分类号: C07C271/34 , C07D207/32 , C07D207/327 , C07D213/56 , C07D213/89 , C07D215/12 , C07D231/56 , C07D233/26 , C07D235/16 , C07D243/16 , C07D243/24 , C07D249/18 , C07D261/08 , C07D277/46 , C07D285/06 , C07D307/79 , C07D307/81 , C07D307/82 , C07D333/60 , C07D403/12 , C07D471/04 , A61K31/27 , C07C271/10
CPC分类号: C07D403/12 , C07C271/34 , C07D207/327 , C07D213/56 , C07D213/89 , C07D215/12 , C07D231/56 , C07D233/26 , C07D235/16 , C07D243/16 , C07D243/24 , C07D249/18 , C07D261/08 , C07D277/46 , C07D285/06 , C07D307/79 , C07D307/81 , C07D307/82 , C07D333/60 , C07D471/04 , C07C2103/74
摘要: Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, and opioids. The compounds are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.
摘要翻译: 公开了用作治疗肥胖症,胃肠胃分泌过多,胃泌素依赖性肿瘤或抗精神病药物的新型非天然罂粟脂。 此外,化合物是抗焦虑剂和抗溃疡剂。 这些化合物是可用于预防慢性治疗或使用尼古丁,地西泮,酒精,可卡因,咖啡因和阿片样物质的戒断反应的药剂。 这些化合物也可用于治疗和/或预防恐慌发作。 还公开了药物组合物和使用二趾甲的治疗方法以及制备它们的方法和可用于其制备的新型中间体。 本发明的另一个特征是本发明化合物用于制备诊断组合物的用途。
-
10.
公开(公告)号:US6001866A
公开(公告)日:1999-12-14
申请号:US51002
申请日:1998-03-20
IPC分类号: A61K31/40 , A61K31/454 , A61K31/38 , A61K31/535 , A61K31/54
CPC分类号: A61K31/454 , A61K31/40
摘要: This invention provides a method for treating or preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor of Formula I: ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, nitro, halo, CN, OR.sup.6, NR.sup.6 R.sup.7, --CO.sub.2 R.sup.6, CONR.sup.6 R.sup.7, CH.sub.2 OR.sup.6, or CH.sub.2 NR.sup.6 R.sup.7, and R.sup.2 and R.sup.3, and R.sup.4 and R.sup.5, when attached to adjacent ring atoms, can be --(CH.sub.2).sub.3 or 4 --;in which R.sup.6 and R.sup.7 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl or benzyl, and when taken together with the nitrogen to which they are attached, R.sup.6 and R.sup.7 can complete a cyclic ring having from 3 to 7 carbon atoms; ##STR2## in which R.sup.8, R.sup.8', R.sup.9, and R.sup.9' independently are hydrogen or C.sub.1 -C.sub.6 alkyl, n is 0, 1, or 2, and Z.sup..crclbar. is an anion, and pharmaceutically acceptable salts thereof.
摘要翻译: PCT No.PCT / US96 / 14242 Sec。 371日期:1998年3月20日 102(e)1998年3月20日PCT PCT 1996年9月5日PCT公布。 公开号WO97 / 12613 日本1997年4月10日本发明提供了治疗或预防哺乳动物炎症或动脉粥样硬化的方法,其包括给予有效量的式I的15-LO抑制剂:其中:R1是氢或C1-C6烷基; R2,R3,R4和R5独立地是氢,C1-C6烷基,硝基,卤素,CN,OR6,NR6R7,-CO2R6,CONR6R7,CH2OR6或CH2NR6R7,R2和R3,R4和R5连接到 相邻的环原子可以是 - (CH 2)3或4-; 其中R6和R7独立地是氢,C1-C6烷基,苯基或苄基,当与它们所连接的氮一起时,R6和R7可以完成具有3至7个碳原子的环; 其中R8,R8',R9和R9'独立地是氢或C1-C6烷基,n是0,1或2,并且Z( - )是一个阴离子,及其药学上可接受的盐。
-
-
-
-
-
-
-
-
-